Does not result in QT extension Second-generation oral antihistamine that is non-sedating and long-lasting; loratadine's active metabolite Used to relieve symptoms associated with seasonal and perennial allergic rhinitis and used for chronic idiopathic urticaria
Other names for this medication:
Clarinex-D, Neoclarityn, Clarinex
Similar Products:
Hydroxyzine, Levosalbutamol, Aristocort, Asthalin, Levolin, Loratadine, Atarax, Phenergan, Pulmicort, Advair, Astelin, Combivent, Allegra, Combimist
Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea Elevations of liver enzymes, increased bilirubin, hepatitis General disorders and administration site conditions Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria) Other undesirable effects reported during the post-marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, bradycardia, abnormal behaviour, and aggression. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). A retrospective observational safety study indicated an increased incidence of new-onset seizure in patients 0 to 19 years of age when receiving desloratadine compared with periods not receiving desloratadine.
Eridanus Healthcare is and attempts to be sensitive to your privacy on the Internet. Whenever possible, Eridanus Healthcare will attempt to treat the information about you we receive on the Internet with care deemed reasonable under the circumstances.
The most frequent of adverse reactions reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %). Among patients 5-19 years of age, the adjusted absolute increase was 11.3 (95% CI 2.3-20.2) per 100,000 PY with a background rate of 36.4 per 100,000 PY. Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea Elevations of liver enzymes, increased bilirubin, hepatitis General disorders and administration site conditions Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria) Other undesirable effects reported during the post-marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, bradycardia, abnormal behaviour and aggression. Frequencies are defined as Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to < 1/100), Rare (≥ 1/10, 000 to 1/1,000), Very rare (<1/10,000) and Not known (cannot be estimated from the available data).
To view the entire topic, please log in or purchase a subscription. Handbook covers dosage, side effects, interactions, uses. Includes App for iPhone, iPad, and Android smartphone + tablet.